AstraZeneca’s Imfinzi approved in the European Union and the UK
LONDON: AstraZeneca‘s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four...
AstraZeneca completes Atacand divestment to Cheplapharm in more than 70 countries
LONDON, UK: AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide)...
AstraZeneca signs definitive agreement to acquire Alexion Pharmaceuticals
CAMBRIDGE: AstraZeneca and Alexion Pharmaceuticals Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion, a news release said. Alexion shareholders will receive...
AstraZeneca sells Crestor to Grünenthal in Europe in a $320 million deal
LONDON: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain,...
Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment
BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of...
AstraZeneca agrees to sell commercial rights to Atacand to Cheplapharm Arzneimittel GmbH
LONDON: AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in...
AstraZeneca’s COVID-19 long-acting antibody combination advances into Phase III clinical trials
LONDON: AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside...
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
LONDON: AstraZeneca today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US-listed debt securities from the New...
RenalytixAI, AstraZeneca to develop and launch precision medicine strategies
NEW YORK: Renalytix AI plc announced a collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first...
AstraZeneca announces a three-tranche $3 billion global bond offering
LONDON: AstraZeneca PLC announces that, on 3 August 2020, it priced a three tranche global bond offering totalling $3bn. The offering is expected to close...
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment
LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen...
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine
LONDON: AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400...